News on companion diagnostics and drug/test co-development.
The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.
